FDA green lights Priovant drug for rare skin disease
BioPharma Dive
Lisraya s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.
pharminent
August 28, 2026 (Last updated: September 1, 2026)
BioPharma Dive
Lisraya s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.